Eggerthella

Eggerthella is a genus of Gram-positive, strictly anaerobic, non-spore-forming bacteria in the family Eggerthellaceae (phylum Actinobacteria). The most studied species, Eggerthella lenta, was originally classified as Eubacterium lentum before reclassification. It is a normal resident of the human colon at low abundance, but its metabolic versatility — particularly its ability to degrade drugs and hormones — makes it disproportionately influential.

What distinguishes Eggerthella from a WikiBiome perspective is its role at the intersection of drug metabolism, hormone recirculation, and metal-tolerant opportunism. It participates in an interspecies metabolic relay with enterococcus faecalis that degrades levodopa in the gut, directly affecting Parkinson's disease treatment. It also expands in metal-disturbed ecosystems where Clostridia are depleted, marking it as an indicator of heavy metal-driven dysbiosis.

Metal Dependencies

Eggerthella lenta relies on several metal cofactors for its diverse reductase enzymes:

  • Iron: Required for electron transport chains in anaerobic respiration. E. lenta uses iron-containing oxidoreductases for its dehydroxylation reactions.
  • Cobalt: The cardiac glycoside reductase (Cgr) operon that inactivates digoxin requires cobalamin (vitamin B12) as a cofactor, linking cobalt availability to drug metabolism.
  • Molybdenum: Molybdopterin-dependent enzymes participate in the reductive metabolism that defines the genus.

Unlike many strict anaerobes that are sensitive to heavy metals, Eggerthella appears to be metal-tolerant. In multiple sclerosis cohorts, E. lenta expands precisely when metal-sensitive Clostridia are depleted — a pattern consistent with cadmium, lead, and nickel exposure selectively removing competitors ([1], cross-sectional).

Key Enzymes and Virulence Factors

  • Dopamine dehydroxylase: E. lenta converts dopamine to m-tyramine through dehydroxylation, forming the second step of an interspecies relay where enterococcus faecalis first converts L-DOPA to dopamine via tyrosine decarboxylase (TyrDC). This two-step pathway significantly reduces levodopa bioavailability in Parkinson's disease patients ([2], in-vitro).
  • Cardiac glycoside reductase (Cgr): Inactivates digoxin in the gut lumen, reducing drug efficacy. This enzyme is strain-specific — only E. lenta strains carrying the Cgr operon metabolize digoxin ([3], expert-opinion).
  • Beta-glucuronidase: Deconjugates glucuronidated estrogens, returning active estrogen to the circulation. This activity connects Eggerthella to the estrobolome and estrogen-dependent conditions.

Ecological Role

In the healthy gut, E. lenta occupies a low-abundance niche as part of the Actinobacteria minority. It becomes ecologically significant under two conditions:

  1. Competitor depletion: When metal-sensitive Clostridia (clusters IV and XIVa) are depleted by heavy metal exposure or other stressors, Eggerthella fills the vacated anaerobic niches. This is the pattern observed in MS, where E. lenta increases alongside Streptococcus as Clostridia decline ([1], cross-sectional).
  1. Uremic environment: In chronic kidney disease, the accumulation of urea and protein fermentation substrates favors proteolytic bacteria. E. lenta is consistently enriched in CKD patients and contributes to the production of uremic toxins including indoxyl sulfate and p-cresyl sulfate ([4], expert-opinion).

The genus also participates in urolithin production from dietary polyphenols via the closely related family Eggerthellaceae. Urolithin A has anti-inflammatory and neuroprotective effects, providing a rare example where this group contributes beneficial metabolites ([5], expert-opinion).

Conditions Associated

Enriched in:

  • Multiple sclerosis: Significantly increased in Japanese MS patients alongside Streptococcus thermophilus; expansion coincides with depletion of Treg-inducing Clostridia ([1], cross-sectional, n=40). Also reported enriched in European MS cohorts ([6], expert-opinion).
  • Chronic kidney disease: Consistently enriched in CKD; contributes to uremic toxin generation (indoxyl sulfate, p-cresyl sulfate) that accelerates renal decline ([4], expert-opinion).
  • Premature ovarian insufficiency: Abundance significantly increased in POI patients; reversed by hormone replacement therapy. E. lenta induced ovarian fibrosis when administered to mice, an effect ameliorated by estrogen ([7], animal-model).
  • Hashimoto's thyroiditis: Identified among genera with significant differences between HT progression stages ([8], cross-sectional).

Key Studies

StudyFindingEvidence Level
[2]E. lenta dehydroxylates dopamine to m-tyramine; interspecies L-DOPA degradation pathway with E. faecalisIn vitro
[1]Enriched in MS when Clostridia depleted; metal-tolerant opportunist patternCross-sectional
[7]Increased in POI; reversed by HRT; causes ovarian fibrosis in miceAnimal model
[4]Enriched in CKD; uremic toxin producerExpert opinion
[3]Digoxin inactivation via Cgr reductaseExpert opinion

Cross-References

References (9)

  1. Sachiko Miyake, Sangwan Kim, Wataru Suda et al. (2015). Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS ONE. doi:10.1371/journal.pone.0137429
  2. Vayu Maini Rekdal, Emily N Bess, Jordan E Bisanz et al. (2019). Maini Rekdal 2019 -- Discovery and Inhibition of an Interspecies Gut Bacterial Pathway for Levodopa Metabolism. Science. doi:10.1126/science.aau6323
  3. Ramya Sree Maddu, Aarthi Saima Ghanta, Veeresh Pratap (2025). Microbiome-Drug Interactions: A Critical Review of Pharmacokinetic and Pharmacodynamic Modulation. Tropical Journal of Pharmaceutical and Life Sciences. doi:10.61280/tjpls.v12i3.185
  4. Wehedy, Ghali, Matboli (2022). Wehedy et al. 2022 — The Human Microbiome in CKD: A Double-Edged Sword. Frontiers in Medicine. doi:10.3389/fmed.2021.790783
  5. Eduardo Duarte-Silva, Sven G. Meuth, Christina Alves Peixoto (2022). Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment. Frontiers in Neuroscience. doi:10.3389/fnins.2022.885031
  6. Matteo Bronzini, Alessandro Maglione, Rachele Rosso et al. (2023). Feeding the gut microbiome: impact on multiple sclerosis. Frontiers in Immunology. doi:10.3389/fimmu.2023.1176016
  7. Jiang L, Fei H, Tong J et al. (2021). Hormone Replacement Therapy Reverses Gut Microbiome and Serum Metabolome Alterations in Premature Ovarian Insufficiency. Frontiers in Endocrinology. doi:10.3389/fendo.2021.794496
  8. Liu J, Qin X, Lin B et al. (2022). Analysis of gut microbiota diversity in Hashimoto's thyroiditis patients. BMC Microbiology. doi:10.1186/s12866-022-02739-z
  9. Esraa Mohsen, Hesham Haffez, Sandra Ahmed et al. (2025). Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune System. Molecular Neurobiology. doi:10.1007/s12035-025-04728-5